Merck & Co., Inc.
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Januvia (sitagliptin by Year
Januvia (sitagliptin — DPP-4 inhibitor) — Worldwide reported growth YoY (%) (%)
Merck Januvia (sitagliptin: 20.0% in FY2025, up 59.0 pts from a year earlier. That is the highest of the 8 years on record here.
Where the FY2025 figure comes from
“|| Januvia | 1,604 | 1,334 | 20 | 999 | 469 | 113 | 605 | 865 | -30”
Source: Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Reported in Form 8-K Table 3 / 3a / 3b Product Sales.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Januvia (sitagliptin — DPP-4 inhibitor) — Worldwide reported growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 20.0% | +59.0 pts | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | -39.0% | -17.0 pts | Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗ |
| FY2023 | Dec 31, 2023 | -22.0% | – | Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗ |
| FY2021 | Dec 31, 2021 | 1.0% | +6.0 pts | Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗ |
| FY2020 | Dec 31, 2020 | -5.0% | +1.0 pts | Form 8-K (tm213179d2_ex99-1.htm, filed 2021-02-04) ↗ |
| FY2019 | Dec 31, 2019 | -6.0% | -5.0 pts | Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗ |
| FY2018 | Dec 31, 2018 | -1.0% | +3.0 pts | Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗ |
| FY2017 | Dec 31, 2017 | -4.0% | – | Form 8-K (a18-5152_1ex99d1.htm, filed 2018-02-02) ↗ |
Cite this data
StockData. (2026). Merck Januvia (sitagliptin (%), annual FY2017–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-januvia-ww-nom-yoy
See every metric in the Merck KPI table. Data updated Oct 26, 2026.